National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
389
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

McClead, R.E., and S.A.Gregory. 1984. Resistance of bovine colostral anti-cholera toxin antibody to in vitro and in vivo proteolysis. Infect. Immun. 44(2):474–478.

Mekalanos, J.J., D.J.Swartz, G.D.N.Pearson, N.Harford, F.Groyne, and M. de Wilde. 1983. Cholera toxin genes: Nucleotide sequence, deletion analysis, and vaccine development. Nature 306:551–557.

Miller, C.J., R.G.Feachem, and B.S.Drasar. 1985. Cholera epidemiology in developed and developing countries: New thoughts on transmission, seasonality, and control. Lancet I:261–263.

Minassian, D.C., V.Mehra, and B.R.Jones. 1984. Dehydrational crises from severe diarrhoea or heatstroke and risk of cataract. Lancet I:751–753.


New Scientist. 1986. New cholera vaccine will be tested on volunteers. New Scientist 109(1500):23.


Pierce, N.F., W.C.Cray, Jr., J.B.Sacci, Jr., J.P.Craig, R. Germanier, and E.Furer. 1983. Procholeragenoid: A safe and effective antigen for oral immunization against experimental cholera. Infect. Immun. 40(3):1112–1118.


Stock, R.F. 1976. Cholera in Africa. Diffusion of the Disease 1970–1975 with Particular Emphasis on West Africa. African Environmental Special Report 3. Plymouth, U.K.: Clarke, Doble & Brendon, Ltd.

Svennerholm, A.M. In press. Proceedings of Nobel Conference 11, Recent Advances in Vaccines and Drugs Against Diarrhoeal Diseases, Saltsjobaden, Stockholm, Sweden, June 3–6, 1985.

Svennerholm, A.M., M.Jertbon, L.Gothefors, A.Kavim, D.A.Sack, and J.Holmgren. 1983. Current status of an oral B subunit whole cell cholera vaccine. Dev. Biol. Stand. 53:73–79.


Woodward, W.E., R.Gilman, R.Hornick, J.Libonati, and R.Cash. 1976. Efficacy of a live oral cholera vaccine in human volunteers. Dev. Biol. Stand. 33:108–112.

World Health Organization. 1984. Cholera. Week. Epidemiol. Rec. 19: 141–142.

Page
389
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)